Histology and Cytology Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 20.54 Billion |
| Market Size (2029) | USD 38.70 Billion |
| CAGR (2024 - 2029) | 13.51 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Histology and Cytology Market Analysis
The Histology And Cytology Market size is estimated at USD 20.54 billion in 2024, and is expected to reach USD 38.70 billion by 2029, growing at a CAGR of 13.51% during the forecast period (2024-2029).
COVID-19 had a significant impact on the growth of the market. This is mainly due to the development of new cytology and histology tests during the pandemic. For instance, an article published by Frontiers in January 2022 stated a new method for the sputum cytology test without direct contact with specimens during the COVID-19 pandemic. Moreover, in an article published by PubMed Central in February 2021, a study was conducted in India, which showed a 92.6% reduction in cytology samples received during the pandemic. Thus, the development of such new cytology methods and the reduction in cytology tests had a significant impact on the market during the pandemic period. However, as the pandemic has subsided, the studied market is expected to have normal growth during the forecast period of the study.
The propelling factors for the growth of the histology and cytology market include the rising prevalence of cancer, increasing standardization of pathological laboratories, and technological advancements in diagnostic and molecular techniques,
The increasing prevalence of cancer is a major factor driving the market growth as histology and cytology tests are majorly used to diagnose cancer. For instance, according to the data published by the Spanish Network of Cancer Registries in January 2021, an estimated 276.2 thousand new cases of cancer were diagnosed in Spain in the previous year out of which 43.6 thousand were colorectal cancer cases, 35.8 thousand were prostate cancer cases, and 33.4 thousand breast cancer cases were diagnosed.
Moreover, according to an article published by the Indian Journal of Medical Research in November 2022, it was estimated that in India, the incidence of cancer cases would likely increase from 1.46 million in the previous year to 1.57 million in two years. The national average for the year 2022 of the crude rate of incidence per 100,000 was 100.4 for males and 95.6 for females. Thus, the increasing prevalence of cancer worldwide is a major factor driving the market growth.
Furthermore, the developments such as product launches by various organizations and market players are also expected to boost the market growth, leading to a higher adoption of histology and cytology products. For instance, in June 2022, the Fine Needle Aspiration Cytology (FNAC) test facility has been launched at the Almora Medical College. This test helps in the detection of chronic diseases like cancer, at an early stage.
Thus, the above mentioned factors such as the rising prevalence of cancer and the increasing developments such as product launches by various organizations and market players are expected to drive the growth of the studied market during the forecast period. However, safety issues and diagnostic accuracy issues with histopathological and cytopathological tests and the lack of awareness among the public for diagnostic tests are expected to hinder the market growth.
Histology and Cytology Market Trends
Cervical Cancer Segment is Expected to Have a Significant Market Share During the Forecast Period
Cytology tests are useful for both the diagnosis and screening of cervical cancer. The cytology segment has a wide range of applications in cervical cancer types. As companies focus more on molecular diagnosis, cytology is expected to play a vital role in the diagnosis of cervical cancer.
The rising prevalence of cervical cancer is a major factor driving the market growth. For instance, according to the data updated by Cancer Australia in August 2022, an estimated 942 new cases of cervical cancer were diagnosed in Australia in the current year, which will account for 1.3% of the latest female cancer cases diagnosed in the country. Thus, the country's high prevalence of cervical cancer is expected to boost segment growth.
Moreover, according to the data updated by ICO/IARC Information Centre on HPV and Cancer in March 2023, an estimated 4,666 cervical cancer cases are diagnosed in Germany every year, and about 3.2% of women in the general population of Germany are estimated to harbour cervical human papillomavirus (HPV)-16/18 infection at a given time, and 76.5% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the country's high prevalence of HPV-related cervical cancers is also expected to enhance segment growth.
Moreover, the rising cervical cancer screening initiatives are also expected to enhance segment growth. For instance, in December 2021, BC Cancer launched an at-home cervix screening pilot in Central Vancouver Island and the Sunshine Coast in Canada, improving access to screening and helping to prevent cervical cancer.
Thus, owing to the above factors, such as the rising prevalence of cervical cancer, the demand for cervical cancer cytological methods is expected to increase.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to hold a significant market share in the histology and cytology market due to the increasing geriatric population, growing cancer incidence, and rising awareness about cancer screening in this region. For instance, according to the American Cancer Society's report in 2023, over 1.96 million new cancer cases are expected to be diagnosed in the United States in the current year. Additionally, 80% of the people diagnosed with cancer in the United States are 55 or older, and 57% are 65 or older. Thus, due to the high prevalence of cancer and the rising affected geriatric population, the demand for diagnostics contributes to the market's growth.
Moreover, according to the January 2022 update by breastcancer.org, around 1 in 8 women in the country (about 13%) develop invasive breast cancer over their lifetime. The same source reports that, in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, as well as 51,400 new cases of non-invasive (in situ) breast cancer. As per the same source, about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A man's lifetime risk of breast cancer is about 1 in 833. Hence, all these factors are expected to help propel the histology and cytology market.
Product approvals in the United States are also expected to contribute to the market's growth. For instance, in May 2021, Hologic received the United States Food and Drug Administration's premarket approval of the Company's ThinPrep Genesis processor for cytology processing and specimen transfer for downstream applications.
Furthermore, awareness about advanced therapeutics and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Histology and Cytology Industry Overview
The histology and cytology market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the key players operating are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Hologic Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., and Trivitron Healthcare.
Histology and Cytology Market Leaders
-
Abbott Laboratories
-
Becton Dickinson and Company
-
Merck KGaA
-
F. Hoffmann-La Roche Ltd
-
Hologic Inc
*Disclaimer: Major Players sorted in no particular order
Histology and Cytology Market News
- February 2023: BioReference Health LLC announced today it would be one of the first commercial laboratories to offer the CINtec PLUS Cytology test from Roche Diagnostics. CINtec PLUS Cytology is the only FDA-approved dual-stain triage test for patients who have a positive high-risk human papillomavirus (HPV) result.
- July 2022: Nanostics Inc. launched a prospective clinical study to validate a novel and minimally invasive bladder cancer diagnostic test, Clarity DX Bladder, using its Clarity DX diagnostic platform.
Histology and Cytology Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Cancer
- 4.2.2 Increasing Standardization of Pathological Laboratories
- 4.2.3 Technological Advancements in Diagnostic and Molecular Techniques
-
4.3 Market Restraints
- 4.3.1 Safety Issues and Diagnostic Accuracy Issues with Histopathological and Cytopathological Tests
- 4.3.2 Lack of Awareness among the Public for Diagnostic Tests
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Type of Examination
- 5.1.1 Histology
- 5.1.2 Cytology
- 5.1.2.1 Breast Cancer
- 5.1.2.2 Cervical Cancer
- 5.1.2.3 Others
-
5.2 By Test Type
- 5.2.1 Microscopy Tests
- 5.2.1.1 Cytogenic Tests
- 5.2.1.1.1 Karyotyping
- 5.2.1.1.2 Fluorescent In-situ Hybridization (FISH)
- 5.2.1.2 Polymerase Chain Reaction
- 5.2.1.3 Other Microscopy Tests
- 5.2.2 Molecular Genetics Tests
- 5.2.3 Flow Cytomtery
-
5.3 By End User
- 5.3.1 Hospitals and Clinics
- 5.3.2 Academic and Research Institutes
- 5.3.3 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott
- 6.1.2 Becton Dickinson and Company
- 6.1.3 Danaher Corporation
- 6.1.4 F. Hoffmann-La Roche Ltd
- 6.1.5 Hologic Inc.
- 6.1.6 Merck KGaA
- 6.1.7 PerkinElmer Inc.
- 6.1.8 Sysmex Corporation
- 6.1.9 Thermo Fisher Scientific Inc.
- 6.1.10 Trivitron Healthcare
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityHistology and Cytology Industry Segmentation
As per the scope of the report, cytology and histology are two different branches of pathology, where cytology mainly involves looking at individual cells or clusters of cells, and histology involves examining an entire section of tissue containing many types of cells.
The Histology and Cytology Market is Segmented by Type of Examination (Histology and Cytology), Test Type (Microscopy Tests, Molecular Genetics Tests and Flow Cytometry), End-User (Hospitals and Clinics, Academic and Research Institutes. and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Type of Examination | Histology | ||
| Cytology | Breast Cancer | ||
| Cervical Cancer | |||
| Others | |||
| By Test Type | Microscopy Tests | Cytogenic Tests | Karyotyping |
| Fluorescent In-situ Hybridization (FISH) | |||
| By Test Type | Microscopy Tests | Polymerase Chain Reaction | |
| Other Microscopy Tests | |||
| By Test Type | Molecular Genetics Tests | ||
| Flow Cytomtery | |||
| By End User | Hospitals and Clinics | ||
| Academic and Research Institutes | |||
| Other End Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Geography | Europe | Germany | |
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Geography | Asia-Pacific | China | |
| Japan | |||
| India | |||
| Australia | |||
| South korea | |||
| Rest of Asia-Pacific | |||
| Geography | Middle East and Africa | GCC | |
| South Africa | |||
| Rest of Middle East and Africa | |||
| Geography | South America | Brazil | |
| Argentina | |||
| Rest of South America |
Histology and Cytology Market Research FAQs
How big is the Histology And Cytology Market?
The Histology And Cytology Market size is expected to reach USD 20.54 billion in 2024 and grow at a CAGR of 13.51% to reach USD 38.70 billion by 2029.
What is the current Histology And Cytology Market size?
In 2024, the Histology And Cytology Market size is expected to reach USD 20.54 billion.
Who are the key players in Histology And Cytology Market?
Abbott Laboratories, Becton Dickinson and Company, Merck KGaA, F. Hoffmann-La Roche Ltd and Hologic Inc are the major companies operating in the Histology And Cytology Market.
Which is the fastest growing region in Histology And Cytology Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Histology And Cytology Market?
In 2024, the North America accounts for the largest market share in Histology And Cytology Market.
What years does this Histology And Cytology Market cover, and what was the market size in 2023?
In 2023, the Histology And Cytology Market size was estimated at USD 17.77 billion. The report covers the Histology And Cytology Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Histology And Cytology Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the major challenges in the Histology and Cytology Market?
The major challenges in the Histology and Cytology Market are a) Increasing pressure to reduce healthcare spending can limit investment in laboratory infrastructure and advanced technologies b) Implementing and maintaining rigorous quality control measures requires ongoing effort and resources
What are the major challenges in the Histology and Cytology Market?
The major challenges in the Histology and Cytology Market are a) Increasing pressure to reduce healthcare spending can limit investment in laboratory infrastructure and advanced technologies b) Implementing and maintaining rigorous quality control measures requires ongoing effort and resources
Histology and Cytology Industry Report
The global histology and cytology market is on an upswing, fueled by the growing incidence of cell-based diseases, such as cancer, and heightened demand for accurate tissue and cell analysis. Digital cytology systems and the application of immunohistochemistry are revolutionizing diagnosis, making way for effective disease detection and management. With the cytology segment taking the lead, particularly for breast and cervical cancer through cost-effective screening methods like FNAC and Pap smear, there's a noticeable impact on mortality rates. The market also benefits from advancements in consumables, reagents, and software systems, essential for the routine adoption and innovation in this field. The drug discovery segment, powered by histomorphometry and IHC staining, alongside North America's robust R&D landscape and Asia Pacific's surging growth due to increased cancer awareness, signals a promising future driven by digital innovations and early detection strategies. Mordor Intelligence™ provides detailed market insights, highlighting this sector's expansion and future prospects. Statistics for the Histology and Cytology market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Histology and Cytology analysis includes a market forecast outlook and historical overview. Get a sample of this industry analysis as a free report PDF download.
